Common Contracts
1 similar Stock Purchase Agreement contracts
PROPOSED MERGERStock Purchase Agreement • January 28th, 2022
Tocagen Inc. (“Tocagen”) and Forte Biosciences, Inc. (“Forte”) have entered into an Agreement and Plan of Merger and Reorganization, dated February 19, 2020, as amended on May 11, 2020 and as may be further amended from time to time (the “Merger Agreement”), pursuant to which a wholly owned subsidiary of Tocagen will merge with and into Forte, with Forte surviving as a wholly owned subsidiary of Tocagen (the “Merger”). The Merger will result in a clinical-stage biopharmaceutical company focused on advancing Forte’s clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients for which there is currently a significant unmet need for safe and effective therapies.
